NO20074567L - Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse - Google Patents

Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse

Info

Publication number
NO20074567L
NO20074567L NO20074567A NO20074567A NO20074567L NO 20074567 L NO20074567 L NO 20074567L NO 20074567 A NO20074567 A NO 20074567A NO 20074567 A NO20074567 A NO 20074567A NO 20074567 L NO20074567 L NO 20074567L
Authority
NO
Norway
Prior art keywords
compounds
glucagon receptor
preparation
methods
receptor antagonists
Prior art date
Application number
NO20074567A
Other languages
English (en)
Inventor
Scott Eugene Conner
Mark Donald Chappell
Allie Edward Tripp
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074567(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20074567L publication Critical patent/NO20074567L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Foreliggende oppfinnelse beskriver nye forbindelser med formel I eller farmasøytisk akseptable salter derav som har glukagon reseptorantagonist eller invers-agonistisk aktivitet, så vel som fremgangsmåter for anvendelse av disse forbindelsene og intermediatene og fremgangsmåter for fremstilling av slike forbindelser. I en annen utførelsesform beskriver foreliggende oppfinnelse farmasøytiske sammensetninger som innbefatter forbindelser med formel I så vel som fremgangsmåter for anvendelse av dem for behandling av diabetiske og andre glukagonrelaterte metabolske forstyrrelser, og lignende.
NO20074567A 2005-02-11 2007-09-10 Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse NO20074567L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
PCT/US2006/004461 WO2006086488A2 (en) 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
NO20074567L true NO20074567L (no) 2007-11-08

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074567A NO20074567L (no) 2005-02-11 2007-09-10 Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse

Country Status (25)

Country Link
US (1) US8084489B2 (no)
EP (1) EP1856090B1 (no)
JP (1) JP4988604B2 (no)
KR (1) KR20070104409A (no)
CN (1) CN101115735B (no)
AT (1) ATE445609T1 (no)
AU (1) AU2006213894B2 (no)
BR (1) BRPI0607015A2 (no)
CA (1) CA2597073C (no)
CR (1) CR9304A (no)
CY (1) CY1109624T1 (no)
DE (1) DE602006009773D1 (no)
DK (1) DK1856090T3 (no)
EA (1) EA200701705A1 (no)
ES (1) ES2332470T3 (no)
IL (1) IL184932A0 (no)
MA (1) MA29432B1 (no)
MX (1) MX2007009661A (no)
NO (1) NO20074567L (no)
PL (1) PL1856090T3 (no)
PT (1) PT1856090E (no)
SI (1) SI1856090T1 (no)
TN (1) TNSN07313A1 (no)
WO (1) WO2006086488A2 (no)
ZA (1) ZA200706354B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512058A (pt) * 2004-06-14 2008-02-06 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
CN105566265A (zh) 2007-02-09 2016-05-11 症变治疗公司 新颖的胰高血糖素受体拮抗剂
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2714207T3 (es) 2008-08-13 2019-05-27 Metabasis Therapeutics Inc Antagonistas de glucagón
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
DK2673260T3 (en) 2011-02-08 2016-10-10 Pfizer Glucagonreceptormodulator
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN ANALOGUES (1-7) AND ASSOCIATED METHODS
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
EP3506940A1 (en) 2016-08-30 2019-07-10 Regeneron Pharmaceuticals, Inc. Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
JP2020531532A (ja) 2017-08-22 2020-11-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
US20210121422A1 (en) 2018-02-13 2021-04-29 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
WO2021123051A1 (en) 2019-12-20 2021-06-24 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463715A1 (en) * 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
AU2003233780A1 (en) * 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
US7989457B2 (en) * 2004-05-28 2011-08-02 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0512058A (pt) 2004-06-14 2008-02-06 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
CA2597073A1 (en) 2006-08-17
PT1856090E (pt) 2009-11-18
IL184932A0 (en) 2007-12-03
DE602006009773D1 (de) 2009-11-26
TNSN07313A1 (en) 2008-12-31
ZA200706354B (en) 2008-11-26
WO2006086488A2 (en) 2006-08-17
CA2597073C (en) 2014-11-25
JP2008530102A (ja) 2008-08-07
ES2332470T3 (es) 2010-02-05
DK1856090T3 (da) 2009-11-30
AU2006213894A1 (en) 2006-08-17
PL1856090T3 (pl) 2010-02-26
CN101115735A (zh) 2008-01-30
CN101115735B (zh) 2013-01-09
US20100137417A1 (en) 2010-06-03
EP1856090B1 (en) 2009-10-14
MA29432B1 (fr) 2008-05-02
ATE445609T1 (de) 2009-10-15
CR9304A (es) 2008-03-31
EA200701705A1 (ru) 2008-02-28
SI1856090T1 (sl) 2010-02-26
BRPI0607015A2 (pt) 2009-12-01
CY1109624T1 (el) 2014-08-13
JP4988604B2 (ja) 2012-08-01
EP1856090A2 (en) 2007-11-21
AU2006213894B2 (en) 2011-12-08
WO2006086488A3 (en) 2006-12-14
MX2007009661A (es) 2007-09-25
KR20070104409A (ko) 2007-10-25
US8084489B2 (en) 2011-12-27

Similar Documents

Publication Publication Date Title
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
DK1758853T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application